DAY TWO WATCH LIVE (EST); 20/10/20keyboard_arrow_right
Search keyboard_arrow_right
keyboard_arrow_left Hide
DAY TWO WATCH LIVE (EST); 20/10/20
search
DAY TWO WATCH LIVE (EST); 20/10/20
search
This agenda is just the start. Wherever you are in the world, the Cell Therapy Bioprocessing & Commercialization and Cell Therapy Manufacturing & Gene Therapy Congresses are coming to you. The talks listed here are just the tip of the iceberg. Please also make sure to browse all of our 'on-demand' sessions which available to watch at your convenience.
DAY TWO WATCH LIVE (EST); 20/10/20 8:00am - 8:30am30 mins
Cell Therapy
Lets get moving PT session
DAY TWO WATCH LIVE (EST); 20/10/20 8:00am - 8:30am30 mins
Gene Edited Ex Vivo Cell Therapy
Lets get moving PT session
DAY TWO WATCH LIVE (EST); 20/10/20 8:00am - 8:30am30 mins
In Vivo Gene Therapy
Lets get moving PT session
DAY TWO WATCH LIVE (EST); 20/10/20 8:00am - 8:30am30 mins
Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
Lets get moving PT session
DAY TWO WATCH LIVE (EST); 20/10/20 8:30am - 9:00am30 mins
Cell Therapy
Exhibtion Viewing Time & Networking Breakfast
DAY TWO WATCH LIVE (EST); 20/10/20 8:30am - 9:00am30 mins
Gene Edited Ex Vivo Cell Therapy
Exhibtion Viewing Time & Networking Breakfast
DAY TWO WATCH LIVE (EST); 20/10/20 8:30am - 9:00am30 mins
In Vivo Gene Therapy
Exhibtion Viewing Time & Networking Breakfast
DAY TWO WATCH LIVE (EST); 20/10/20 8:30am - 9:00am30 mins
Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
Exhibtion Viewing Time & Networking Breakfast
DAY TWO WATCH LIVE (EST); 20/10/20 9:00am - 9:10am10 mins
Cell Therapy
Chairperson’s Opening Remarks
- David Smith - President and Chief Commercial Officer, Akron Biotech, USA
DAY TWO WATCH LIVE (EST); 20/10/20 9:00am - 9:10am10 mins
Gene Edited Ex Vivo Cell Therapy
Chairperson’s Opening Remarks
- David Smith - President and Chief Commercial Officer, Akron Biotech, USA
DAY TWO WATCH LIVE (EST); 20/10/20 9:00am - 9:10am10 mins
In Vivo Gene Therapy
Chairperson’s Opening Remarks
- David Smith - President and Chief Commercial Officer, Akron Biotech, USA
DAY TWO WATCH LIVE (EST); 20/10/20 9:00am - 9:10am10 mins
Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
Chairperson’s Opening Remarks
- David Smith - President and Chief Commercial Officer, Akron Biotech, USA
DAY TWO WATCH LIVE (EST); 20/10/20 9:10am - 9:30am20 mins
Cell Therapy
Fate Therapeutic’s Off-the-shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy Programs
- Betsy Rezner - Director, Process & Assay Development, Fate Therapeutics Inc.
DAY TWO WATCH LIVE (EST); 20/10/20 9:10am - 9:30am20 mins
Gene Edited Ex Vivo Cell Therapy
Fate Therapeutic’s Off-the-shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy Programs
- Betsy Rezner - Director, Process & Assay Development, Fate Therapeutics Inc.
DAY TWO WATCH LIVE (EST); 20/10/20 9:10am - 9:30am20 mins
In Vivo Gene Therapy
Fate Therapeutic’s Off-the-shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy Programs
- Betsy Rezner - Director, Process & Assay Development, Fate Therapeutics Inc.
DAY TWO WATCH LIVE (EST); 20/10/20 9:10am - 9:30am20 mins
Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
Fate Therapeutic’s Off-the-shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy Programs
- Betsy Rezner - Director, Process & Assay Development, Fate Therapeutics Inc.
DAY TWO WATCH LIVE (EST); 20/10/20 9:30am - 9:50am20 mins
Cell Therapy
Scalable Manufacture Platform of Human iPS-NK Cells for Off-the-Shelf Cell Therapies
- Allen Feng - Chief Scientific Officer, HebeCell Corp., USA
DAY TWO WATCH LIVE (EST); 20/10/20 9:30am - 9:50am20 mins
Gene Edited Ex Vivo Cell Therapy
Scalable Manufacture Platform of Human iPS-NK Cells for Off-the-Shelf Cell Therapies
- Allen Feng - Chief Scientific Officer, HebeCell Corp., USA
DAY TWO WATCH LIVE (EST); 20/10/20 9:30am - 9:50am20 mins
In Vivo Gene Therapy
Scalable Manufacture Platform of Human iPS-NK Cells for Off-the-Shelf Cell Therapies
- Allen Feng - Chief Scientific Officer, HebeCell Corp., USA
DAY TWO WATCH LIVE (EST); 20/10/20 9:30am - 9:50am20 mins
Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
Scalable Manufacture Platform of Human iPS-NK Cells for Off-the-Shelf Cell Therapies
- Allen Feng - Chief Scientific Officer, HebeCell Corp., USA
DAY TWO WATCH LIVE (EST); 20/10/20 9:50am - 10:10am20 mins
Cell Therapy
Non-Gene Edited Approaches to Allogeneic CAR-T Cell Therapy
- Philippe Parone - Director, Industrialization, Celyad, Belgium
DAY TWO WATCH LIVE (EST); 20/10/20 9:50am - 10:10am20 mins
Gene Edited Ex Vivo Cell Therapy
Non-Gene Edited Approaches to Allogeneic CAR-T Cell Therapy
- Philippe Parone - Director, Industrialization, Celyad, Belgium
DAY TWO WATCH LIVE (EST); 20/10/20 9:50am - 10:10am20 mins
In Vivo Gene Therapy
Non-Gene Edited Approaches to Allogeneic CAR-T Cell Therapy
- Philippe Parone - Director, Industrialization, Celyad, Belgium
DAY TWO WATCH LIVE (EST); 20/10/20 9:50am - 10:10am20 mins
Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
Non-Gene Edited Approaches to Allogeneic CAR-T Cell Therapy
- Philippe Parone - Director, Industrialization, Celyad, Belgium
DAY TWO WATCH LIVE (EST); 20/10/20 10:10am - 10:30am20 mins
Cell Therapy
The Potential CAR-NK
- Kathryn Corzo - Head of Development Oncology Cell Therapies, Takeda
DAY TWO WATCH LIVE (EST); 20/10/20 10:10am - 10:30am20 mins
Gene Edited Ex Vivo Cell Therapy
The Potential CAR-NK
- Kathryn Corzo - Head of Development Oncology Cell Therapies, Takeda
DAY TWO WATCH LIVE (EST); 20/10/20 10:10am - 10:30am20 mins
In Vivo Gene Therapy
The Potential CAR-NK
- Kathryn Corzo - Head of Development Oncology Cell Therapies, Takeda
DAY TWO WATCH LIVE (EST); 20/10/20 10:10am - 10:30am20 mins
Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
The Potential CAR-NK
- Kathryn Corzo - Head of Development Oncology Cell Therapies, Takeda
DAY TWO WATCH LIVE (EST); 20/10/20 10:30am - 11:00am30 mins
Cell Therapy
Data driven strategies for downstream processing of Plasmid DNA in viral vector production
- Thomas Parker - Process Development Scientist, Global Focal Point for Vaccines and Viral Therapies, MilliporeSigma
DAY TWO WATCH LIVE (EST); 20/10/20 10:30am - 11:00am30 mins
Gene Edited Ex Vivo Cell Therapy
Data driven strategies for downstream processing of Plasmid DNA in viral vector production
- Thomas Parker - Process Development Scientist, Global Focal Point for Vaccines and Viral Therapies, MilliporeSigma
DAY TWO WATCH LIVE (EST); 20/10/20 10:30am - 11:00am30 mins
In Vivo Gene Therapy
Data driven strategies for downstream processing of Plasmid DNA in viral vector production
- Thomas Parker - Process Development Scientist, Global Focal Point for Vaccines and Viral Therapies, MilliporeSigma
DAY TWO WATCH LIVE (EST); 20/10/20 10:30am - 11:00am30 mins
Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
Data driven strategies for downstream processing of Plasmid DNA in viral vector production
- Thomas Parker - Process Development Scientist, Global Focal Point for Vaccines and Viral Therapies, MilliporeSigma
DAY TWO WATCH LIVE (EST); 20/10/20 11:00am - 11:20am20 mins
Cell Therapy
Starting Material Standardization
- Christiane Niederlaender - Director, AMBR Consulting Ltd, formerly MHRA, UK
DAY TWO WATCH LIVE (EST); 20/10/20 11:00am - 11:20am20 mins
Gene Edited Ex Vivo Cell Therapy
Starting Material Standardization
- Christiane Niederlaender - Director, AMBR Consulting Ltd, formerly MHRA, UK
DAY TWO WATCH LIVE (EST); 20/10/20 11:00am - 11:20am20 mins
In Vivo Gene Therapy
Starting Material Standardization
- Christiane Niederlaender - Director, AMBR Consulting Ltd, formerly MHRA, UK
DAY TWO WATCH LIVE (EST); 20/10/20 11:00am - 11:20am20 mins
Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
Scaffold Fabrication
- Michael Francis - Chief Scientific Officer - Co-Founder, Embody, Faculty at EVMS
DAY TWO WATCH LIVE (EST); 20/10/20 11:20am - 11:45am25 mins
Cell Therapy
Speaker Q&A - Raw Material, Viral Vector & Supply Chain Considerations
- Christopher Bravery - Director, Consulting on Advanced Biologicals Ltd., Member, ISCT EU Legal and Regulatory Affairs Committee, UK
- Christiane Niederlaender - Director, AMBR Consulting Ltd, formerly MHRA, UK
- Scott Burger - Principal, Advanced Cell & Gene Therapy, USA
- Tom Walls - Global Planning and Logistics Lead, Spark Therapeutics, USA
- Max Sellman - Product Manager, Gene Editing, Aldevron, USA
- Sylvain Cecchini - Associate Professor of Microbiology & Physiological Systems, University of Massachusetts Medical School, USA
DAY TWO WATCH LIVE (EST); 20/10/20 11:20am - 11:45am25 mins
Gene Edited Ex Vivo Cell Therapy
Speaker Q&A - Raw Material, Viral Vector & Supply Chain Considerations
- Christopher Bravery - Director, Consulting on Advanced Biologicals Ltd., Member, ISCT EU Legal and Regulatory Affairs Committee, UK
- Christiane Niederlaender - Director, AMBR Consulting Ltd, formerly MHRA, UK
- Scott Burger - Principal, Advanced Cell & Gene Therapy, USA
- Tom Walls - Global Planning and Logistics Lead, Spark Therapeutics, USA
- Max Sellman - Product Manager, Gene Editing, Aldevron, USA
- Sylvain Cecchini - Associate Professor of Microbiology & Physiological Systems, University of Massachusetts Medical School, USA
DAY TWO WATCH LIVE (EST); 20/10/20 11:20am - 11:45am25 mins
In Vivo Gene Therapy
Speaker Q&A - Raw Material, Viral Vector & Supply Chain Considerations
- Christopher Bravery - Director, Consulting on Advanced Biologicals Ltd., Member, ISCT EU Legal and Regulatory Affairs Committee, UK
- Christiane Niederlaender - Director, AMBR Consulting Ltd, formerly MHRA, UK
- Scott Burger - Principal, Advanced Cell & Gene Therapy, USA
- Tom Walls - Global Planning and Logistics Lead, Spark Therapeutics, USA
- Max Sellman - Product Manager, Gene Editing, Aldevron, USA
- Sylvain Cecchini - Associate Professor of Microbiology & Physiological Systems, University of Massachusetts Medical School, USA
DAY TWO WATCH LIVE (EST); 20/10/20 11:20am - 11:45am25 mins
Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
Speaker Q&A
- Mary Clare McCorry - Director, Technology and Process Development, Advanced Regenerative Manufacturing Institute (ARMI)
- Michael Francis - Chief Scientific Officer - Co-Founder, Embody, Faculty at EVMS
- Benjamin Fryer - Founder, Pluristyx, Incorporated, USA
- Sonia Bulsara - Application Specialist Manager, US & Canada, Cell and Gene Therapy, Cytiva, USA
- Jan Jensen - CEO and Founder, Trailhead Biosystems Inc.
DAY TWO WATCH LIVE (EST); 20/10/20 11:45am - 12:30pm45 mins
Cell Therapy
Networking & Additional Content Viewing Time
DAY TWO WATCH LIVE (EST); 20/10/20 11:45am - 12:30pm45 mins
Gene Edited Ex Vivo Cell Therapy
Networking & Additional Content Viewing Time
DAY TWO WATCH LIVE (EST); 20/10/20 11:45am - 12:30pm45 mins
In Vivo Gene Therapy
Networking & Additional Content Viewing Time
DAY TWO WATCH LIVE (EST); 20/10/20 11:45am - 12:30pm45 mins
Advanced Tools for Cell and Tissue Manufacturing: 20/20 View
Networking & Additional Content Viewing Time
Get the latest news.
As it happens
Sign up to get the latest on the agenda and speakers.
Choose Day
- WATCH ON DEMAND: Industry PresentationsWATCH ON DEMAND: Industry Presentations
- DAY ONE WATCH LIVE (EST); 19/10/20DAY ONE WATCH LIVE (EST); 19/10/20
- DAY TWO WATCH LIVE (EST); 20/10/20DAY TWO WATCH LIVE (EST); 20/10/20
- DAY THREE WATCH LIVE (EST); 21/10/20DAY THREE WATCH LIVE (EST); 21/10/20
- DAY FOUR WATCH LIVE (EST); 22/10/20DAY FOUR WATCH LIVE (EST); 22/10/20
- WATCH ON DEMAND: Spotlight PresentationsWATCH ON DEMAND: Spotlight Presentations
- Download Agenda